Incyte Bets $1.25 Billion On Rare Bleeding Disorder Drug With Blockbuster Potential

Incyte Corporation agreed to acquire Vega Therapeutics for $1.25 billion upfront to add VGA039, a late-stage monoclonal antibody candidate for von Willebrand disease, to its hematology portfolio. The deal could reach $2 billion with milestone payments. VGA039, in Phase 3 development, has potential to become the first subcutaneous prophylactic treatment for VWD and analysts project blockbuster commercial potential with over $1 billion market opportunity.